Pazdur, Richard

FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist

Cutaneous lymphoproliferative disorders researchDermatology and Skin Diseases

Cited by 1,365

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 1,176

Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration

Talarico, L., Chen, G., & Pazdur, R. (2004) · Journal of Clinical Oncology

Ethics in Clinical ResearchFrailty in Older Adults

Cited by 727

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

Nakajima, E. C., Drezner, N., Li, X., Mishra-Kalyani, P. S., Liu, Y., Zhao, H., Bi, Y., Liu, J., Rahman, A., Wearne, E., et al. (2022) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 333

Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody

Maher, V. E., Fernandes, L. L., Weinstock, C., Tang, S., Agarwal, S., Brave, M., Ning, Y.-M., Singh, H., Suzman, D., Xu, J., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 331

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Fallah, J., Agrawal, S., Gittleman, H., Fiero, M. H., Subramaniam, S., John, C., Chen, W., Ricks, T. K., Niu, G., Fotenos, A., et al. (2023) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 255

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

Fallah, J., Brave, M. H., Weinstock, C., Mehta, G. U., Bradford, D., Gittleman, H., Bloomquist, E. W., Charlab, R., Hamed, S. S., Miller, C. P., et al. (2022) · Clinical Cancer Research

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 180

Seamless Oncology-Drug Development

Prowell, T. M., Theoret, M. R., & Pazdur, R. (2016) · New England Journal of Medicine

Statistical Methods in Clinical TrialsPharmaceutical studies and practices

Cited by 126

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Shah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 105

FDA analyses of survival in older adults with metastatic non–small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies

Marur, S., Singh, H., Mishra-Kalyani, P., Larkins, E., Keegan, P., Sridhara, R., Blumenthal, G. M., & Pazdur, R. (2018) · Seminars in Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 100

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

Singh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 99

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

Fallah, J., Xu, J., Weinstock, C., Gao, X., Heiss, B. L., Maguire, W. F., Chang, E., Agrawal, S., Tang, S., Amiri-Kordestani, L., et al. (2024) · Journal of Clinical Oncology

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 86

Remote Monitoring and Data Collection for Decentralized Clinical Trials

Daly, B., Brawley, O. W., Gospodarowicz, M. K., Olopade, O. I., Fashoyin-Aje, L., Smart, V. W., Chang, I.-F., Tendler, C. L., Kim, G., Fuchs, C. S., et al. (2024) · JAMA Network Open

Telemedicine and Telehealth ImplementationStatistical Methods in Clinical Trials

Cited by 38

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Gandhy, S. U., Casak, S. J., Mushti, S. L., Cheng, J., Subramaniam, S., Zhao, H., Zhao, M., Bi, Y., Liu, G., Fan, J., et al. (2023) · Clinical Cancer Research

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 25